INSM
Insmed, Inc.Data: 2026-10-22
Quick Stats
Oct 22, 202651.6
AI Score
HOLD0.7
Volume Ratio
Oct 29, 2026
Next Earnings
12
+ve Days (30d)
18
-ve Days (30d)
INSM Price vs Max Options Open Interest
How to read this: the line is the stock price; the bars show where the most option open interest sits each day. Strikes with heavy open interest often act as magnets or barriers for price ("max pain" zones). Scroll right for the most recent days.
INSM Max Change In Options Open Interest
How to read this: each bar is the option contract whose open interest changed the most yesterday. Green bars = new positions being opened (conviction building at that strike); red bars = positions being closed. Call builds above the current price suggest upside bets; put builds below it suggest hedging or downside bets.
INSM Options - Sort by Max open Interest (near term)
22nd October 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
INSM Daily Out of Money Options - Sort by Max open Interest (near term)
22nd October 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
INSM Daily In the Money Options - Sort by Max open Interest (near term)
22nd October 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
INSM Most Active Options by Volume(near term)
22nd October 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | Volume | OI | Change in OI |
Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
INSM Technical Chart Pro Chart
- Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
- SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
- Options OI: Shows max open interest strikes. High OI = significant price levels.
- Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
- Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
- Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
- Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
- Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Volume Profile Analysis
Horizontal histogram showing volume distribution at each price level with buying/selling pressure
INSM Stock Summary
Last updated Oct 22, 2026
INSM is currently trading at $94.599, positioned below its 200-day moving average of $127.49, suggesting bearish momentum. The stock has a 52-week range of $90.39 to $212.75.
Technical Analysis: The 50-day moving average stands at $115.86, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 27.946, suggesting the stock is oversold and potentially undervalued.
Money Flow Indicators: The Chaikin Money Flow (20-day) is -0.185, which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates INSM at 51.6/100 with a HOLD recommendation.
INSM (Insmed, Inc.) Indicators
Last updated Oct 22, 2026
| Indicator | Value |
|---|---|
| RSI(14) | 27.946 |
| CMF (20) | -0.185 |
| ROC (10) | -6.15 |
| ADX (14) | 46.098 |
| Indicator | Value |
|---|---|
| MACD (12,26,9) | -6.218 |
| AROONOSC (14) | -100.0 |
| WILLAMS %R (14) | -93.709 |
| MFI (14) | 23.177 |
INSM Candlestick Patterns
Validated patterns fired in the last 10 sessions. Hit rate = how often price moved in the signal's direction within 5 trading days (backtest: 2.7M signals, 3,500 liquid stocks, Feb 2025–Sep 2026). Baseline: a random stock closes higher 5 days later 53% of the time. Click a row to see the candle on the chart.
| Date | Pattern | Signal | 5-Day Hit Rate | Edge vs Baseline | Sample |
|---|---|---|---|---|---|
| Oct 22 | Thrusting Line | Bearish | 50.0% | +3.0 pts | 9556 |
| Oct 16 | Marubozu (bearish) (contrarian — textbook says the opposite) | Bullish | 56.2% | +3.2 pts | 30540 |
| Oct 13 | Inverted Hammer | Bullish | 56.4% | +3.4 pts | 19834 |
| Oct 12 | Gravestone Doji | Bullish | 55.2% | +2.2 pts | 21200 |
| Oct 12 | Inverted Hammer | Bullish | 56.4% | +3.4 pts | 19834 |
These are statistical tilts, not standalone trade setups. Only patterns with a measured edge are shown — roughly 50 of 60 textbook patterns showed no edge and are hidden.
Insmed, Inc. is below both the 50 Day and 200 Day SMA which is considered Bearish.
INSM Moving Averages Analysis
INSM (Insmed, Inc.) Simple Moving Averages
Moving Averages are last updated Oct 22, 2026
| Days | MA |
|---|---|
| 10 | 96.93 |
| 20 | 103.28 |
| 30 | 109.62 |
| 50 | 115.86 |
| 100 | 111.36 |
| 200 | 127.49 |
INSM Fundamental Analysis
| P/E (Forward) | 97.0874 |
| P/E (Trailing) | -- |
| Market Cap ($) | 20.9 billion |
| Earnings/Share ($) | -4.1 |
| Net Profit Margin (%) | -0.7694 |
| Dividend/Share ($) | -- |
| EPS Estimate Current Year ($) | -1.5912 |
| EPS Estimate Next Year ($) | 0.7975 |
| WallStreet Target Price ($) | 197.00 |
| Most Recent Quarter |
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.